Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of upfront rotating everolimus and pazopanib versus sequential pazopanib then everolimus in advanced clear cell renal cancer
2011-000127-32Phase 2Completed
- Sponsor
- WIN-O
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of everolimus and pazopanib in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by WIN-O. Primary endpoint: Progression-free survival. Started Jan 2014; status: completed.
02
Drugs
everolimuspazopanib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2011-000127-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000127-32.